Hjem › Leukæmi › Massachusetts › Boston
Leukæmi kliniske forsøg i Boston, MA
25 studier for Leukæmi søger deltagere på steder i og omkring Boston (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RekruttererFase 2
- Dana-Farber Cancer Institute, Boston
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Rekrutterer
- Dana-Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
RekruttererFase 3
- Research Site, Boston
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RekruttererFase 2
- Massachusetts General Hospital, Boston
CIML NK Cells With Venetoclax for AML
RekruttererFase 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
RekruttererFase 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RekruttererFase 1
- Beth Israel Deaconess Medical Center, Boston
ALL Backbone in AYAs
RekruttererFase 2
- Dana Farber Cancer Institute, Boston
Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
Rekrutterer
- Mass General Brigham Cancer Institute, Boston
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
RekruttererFrivillige med god helbredstilstand velkomne
- Dana-Farber Cancer Institute, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
RekruttererFase 1
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
RekruttererFase 1
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
RekruttererFase 1/2
- Dren Investigational Site, Boston
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
RekruttererFase 1
- Dana-Farber Cancer Institute, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
RekruttererObservationsstudie
- Dana-Farber Cancer Institute, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RekruttererFase 2/3
- Dana-Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Rekrutterer
- Massachusetts General Hospital Cancer Center, Boston
Shwachman Diamond Syndrome Registry and Study
RekruttererObservationsstudie
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Revumenib in Combination With 7+3 + Midostaurin in AML
RekruttererFase 1
- Dana-Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RekruttererFase 1
- Massachusetts General Hospital, Boston
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RekruttererFase 1/2
- Dana-Farber Cancer Institute, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RekruttererFase 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
RekruttererFase 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
Rekrutterer
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
HEME Home Transfusion Program
Rekrutterer
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Leukæmi forsøg i andre byer
- Houston, TX28 studier
- New York City, NY19 studier
- Los Angeles, CA16 studier
- Chicago, IL16 studier
- Durham, NC13 studier
- Columbus, OH12 studier
- Nashville, TN12 studier
- Baldwin Park, CA12 studier
- Philadelphia, PA12 studier
- Milwaukee, WI11 studier
- Atlanta, GA11 studier
- Seattle, WA11 studier
Andre studier i Boston
- Brystkræft111 studier
- Ikke-småcellet lungecancer90 studier
- Kræft (alle typer)86 studier
- Colorektal kræft63 studier
- Metastatisk cancer63 studier
- Lungecancer62 studier
- Ægstockræft61 studier
- Prostatakræft59 studier
- Depression52 studier
- Livmoderslimhindekræft50 studier
- Hjertesvigt44 studier
- Akut myeloid leukæmi44 studier
Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.